



Advances in Liver-Targeted Delivery

Guest Editor:

Dr. Ling Li

Division of Gastroenterology and
Hepatology, School of Medicine,
Johns Hopkins University,
Baltimore, MD 21205, USA

Deadline for manuscript
submissions:

closed (20 May 2024)

Message from the Guest Editor

Dear Colleagues,

Promising progress has been achieved in managing liver diseases such as liver cancer, ALD, NASH, HBV and HCV, among others, over the past few decades. Common approaches include systemic drug delivery (intravenous or oral) or localized drug delivery (TACE), which have demonstrated moderate therapeutic outcomes. There remains an urgent need to develop targeted therapies for patients with liver diseases such as liver fibrosis and hepatocellular carcinoma to achieve treatment effects. Prominent strides have been made in biomaterials and nanomedicine, employing diverse targeted therapy approaches designed to deliver drugs and genetic materials to distinct liver cell types afflicted by various diseases. The advent of innovative lipid-based, polymeric, and inorganic nanoparticles, PLGA nanoparticles, liposomes and micelles, alongside gene-editing technologies such as CRISPR/Cas9 or mRNA vaccines and siRNA, mediated through functionalized nanoparticles, holds immense potential in significantly improving therapeutic outcomes for liver diseases. In this Special Issue, original research articles and reviews related to the topic mentioned above are welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of
Pharmacy, Rutgers, The State
University of New Jersey, William
Levine Hall, Room 225C, 160
Frelinghuysen Road, Piscataway,
NJ 08854-8020, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma